1. Show article details.

    10 Biggest Price Target Changes For Tuesday

    Benzinga – 8:23 AM ET 05/17/2022

    Check out this: Snap And 2 Other Stocks Insiders Are Selling Don't forget to check out our premarket coverage here .

  2. Show article details.

    The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More

    Benzinga – 9:38 AM ET 05/16/2022

    Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. On the M&A front, Pfizer, Inc. announced a deal to buy migraine drugmaker Biohaven Pharmaceutical Holding Company Limited in a deal worth $11.6 billion.

  3. Show article details.

    BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share $0.40

    Reuters – 8:13 AM ET 05/16/2022

    Syros Pharmaceuticals Inc (SYRS): * SYROS PHARMACEUTICALS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE. * Q1 LOSS PER SHARE $0.40. * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2022 WERE $112.9 MILLION. * REVENUES WERE $5.5 MILLION FOR Q1 OF 2022.

  4. Show article details.

    Syros Pharmaceuticals: Q1 Earnings Insights

    Benzinga – 7:55 AM ET 05/16/2022

      Syros Pharmaceuticals reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Syros Pharmaceuticals beat estimated earnings by 14.89%, reporting an EPS of $-0.4 versus an estimate of $-0.47. Revenue was up $640.00 thousand from the same period last year.

  5. Show article details.

    Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update

    Business Wire – 7:30 AM ET 05/16/2022

    Three Data Readouts Expected in 2022: Data from the Safety Lead-ins of the SY-5609 Trial in Pancreatic Cancer and of the SELECT-AML-1 Phase 2 Trial; Data from the Dose Confirmation Study of SY-2101 in APL On Track to Report Data from Ongoing SELECT-MDS-1 Pivotal Trial in Q4 2023/Q1 2024 Management to Host Conference Call at 8:30 a.m. ET Today CAMBRIDGE, Mass.

  6. Show article details.

    Earnings Scheduled For May 16, 2022

    Benzinga – 5:18 AM ET 05/16/2022

      ** AcelRx Pharmaceuticals is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. ** Synthetic Biologics is likely to report earnings for its first quarter. ** Passage Bio is estimated to report earnings for its first quarter. ** Taysha Gene Therapies is expected to report earnings for its first quarter.

  7. Show article details.

    Earnings Preview For Syros Pharmaceuticals

    Benzinga – 11:05 AM ET 05/13/2022

    Syros Pharmaceuticals is set to give its latest quarterly earnings report on Monday, 2022-05-16. Analysts estimate that Syros Pharmaceuticals will report an earnings per share of $-0.47. Syros Pharmaceuticals bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

  8. Show article details.

    Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

    Business Wire – 7:30 AM ET 05/09/2022

    Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Monday, May 16, 2022 to report its first quarter 2022 financial results and provide a corporate update. To access the live conference call, please dial 595-4538 or 812-6496 and refer to conference ID 4664097.

  9. Show article details.

    66 Biggest Movers From Yesterday

    Benzinga – 6:08 AM ET 05/03/2022

    66 Biggest Movers From Yesterday

  10. Show article details.

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 4:01 PM ET 04/29/2022

    Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit awards for an aggregate of 136,750 shares of Syros common stock to six newly hired employees in connection with their commencement of employment with Syros.

  11. Show article details.

    Stocks That Hit 52-Week Lows On Thursday

    Benzinga – 3:31 PM ET 04/28/2022

      During Thursday, 849 stocks hit new 52-week lows. During the morning session of trading on Thursday, the following stocks broke to new 52-week lows: Be sure to stay with Benzinga for further updates and market-moving news.

  12. Show article details.

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    Benzinga – 8:31 AM ET 04/26/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  13. Show article details.

    60 Biggest Movers From Yesterday

    Benzinga – 4:58 AM ET 04/26/2022

  14. Show article details.

    56 Biggest Movers From Friday

    Benzinga – 4:23 AM ET 04/25/2022

  15. Show article details.

    Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

    Benzinga – 9:21 AM ET 04/11/2022

    Syros Pharmaceuticals Inc  announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model. 

  16. Show article details.

    Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022

    Business Wire – 1:00 PM ET 04/08/2022

    CDK12 Inhibitor Demonstrates Strong Anti-Tumor Activity as Single Agent and in Combination with a DNA Damaging Agent and a PARP Inhibitor in Models of Breast, Lung, and Ovarian Cancer On Track to Nominate CDK12 Inhibitor as Next Development Candidate in 2H 2022 CAMBRIDGE, Mass. “CDK12 is an attractive cancer target due to its role in transcription and DNA damage repair regulation.

  17. Show article details.

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Business Wire – 4:01 PM ET 04/01/2022

    Syros Pharmaceuticals (SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

  18. Show article details.

    Syros Pharmaceuticals Earnings Perspective: Return On Capital Employed

    Benzinga – 11:05 AM ET 03/16/2022

    According to Benzinga Pro data, during Q4, Syros Pharmaceuticals posted sales of $7.80 million. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

  19. Show article details.

    Recap: Syros Pharmaceuticals Q4 Earnings

    Benzinga – 7:51 AM ET 03/15/2022

      Syros Pharmaceuticals reported its Q4 earnings results on Tuesday, March 15, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Syros Pharmaceuticals beat estimated earnings by 19.15%, reporting an EPS of $-0.38 versus an estimate of $-0.47. Revenue was up $2.10 million from the same period last year.

  20. Show article details.

    The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial

    Benzinga – 7:46 AM ET 03/15/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: Anaptys Bio, Inc. said the Phase 2 clinical trial of imsidolimab for the treatment of moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints.

Page:

Today's and Upcoming Events

  • Aug
    03

    SYRS to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    16

    SYRS announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.